Comparison Study of Acute Ischemic Stroke Patients at Debarattana Nakhon Ratchasima Hospital Who Received rtPA with and Without Intravenous Nicardipine at the First Hospital.
Article Sidebar
Main Article Content
Abstract
Blood pressure control before recombinant tissue plasminogen activator (rtPA) therapy is essential in acute ischemic stroke. This study compared clinical outcomes between patients who received intravenous nicardipine (IV nicardipine) at the first hospital and those who did not. Methods This retrospective cohort study included 213 acute ischemic stroke patients treated with recombinant tissue plasminogen activator (rtPA) at Debarattana Nakhon Ratchasima Hospital during 2020–2023. Sixteen patients received intravenous nicardipine (IV nicardipine), and 197 did not. Results The intravenous nicardipine (IV nicardipine) group had significantly higher systolic blood pressure (SBP) and diastolic blood pressure (DBP) at both hospitals. No significant differences were found in treatment time, symptomatic intracranial hemorrhage (sICH), length of stay, in-hospital mortality, or discharge outcomes. Discussion Interpretation is limited by the small number of patients receiving intravenous nicardipine (IV nicardipine) and differences in baseline characteristics. Conclusion Intravenous nicardipine (IV nicardipine) at the first hospital was associated with higher blood pressure but not with clearly different short-term clinical outcomes.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
สำนักงานหลักประกันสุขภาพแห่งชาติ. รายงานข้อมูลผู้ป่วยโรคหลอดเลือดสมอง [อินเทอร์เน็ต]. นนทบุรี: สำนักงานหลักประกันสุขภาพแห่งชาติ; 2567 [สืบค้นเมื่อ 3 มกราคม 2568]. Available from: https://www.nhso.go.th
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2019 update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418.
สมาคมประสาทวิทยาแห่งประเทศไทย. แนวทางเวชปฏิบัติสำหรับโรคสมองขาดเลือดเฉียบพลัน พ.ศ. 2566 [อินเทอร์เน็ต]. กรุงเทพมหานคร: สมาคมประสาทวิทยาแห่งประเทศไทย; 2566 [สืบค้นเมื่อ 3 มกราคม 2568]. Available from: https://www.neurothai.org
Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Song L, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. Lancet 2019; 393(10174): 877-888.
Bath PM, Martin RH, Palesch Y, Cotton D, Yusuf S, Sacco RL, et al. Effect of telmisartan on functional outcome, recurrent stroke, and cardiovascular events after acute stroke and transient ischemic attack: a meta-analysis. Lancet Neurol 2011; 10(9): 875-884.
Sandset EC, Bath PM, Boysen G, Jatuzis D, Korv J, Lüders S, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377(9767): 741-750.
He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen CS, et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke: the CATIS randomized clinical trial. JAMA 2014; 311(5): 479-489.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359(13): 1317-1329.
Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res 2017; 120(3): 439-448.
Langhorne P, Bernhardt J, Kwakkel G. Stroke rehabilitation. Lancet 2011; 377(9778): 1693-1702.
Feigin VL, Stark BA, Johnson CO, Roth GA, Bisignano C, Abady GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990-2019. Lancet Neurol 2021; 20(10): 795-820.
Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke 2005; 36(12): 2756-2763.
Jørgensen L, Engstad T, Jacobsen BK. Higher incidence of falls in long-term stroke survivors than in population controls. Stroke 2002; 33(2): 542-547.
Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004; 43(1): 18-24.
Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med 2013; 368(25): 2355-2365.
Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med 2016; 375(11): 1033-1043.
Anderson CS, Huang Y, Arima H, Heeley E, Skulina C, Parsons MW, et al. Effects of early intensive blood pressure-lowering treatment on death and major disability in patients with acute intracerebral hemorrhage (INTERACT2). Lancet 2013; 382(9891): 1205-1212.
Bath PM, Scutt P, Anderson CS, Appleton JP, Berge E, Cala L, et al. Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. Lancet 2019; 393(10175): 1009-1020.
